The Impact of Tumor Molecular Profile on Prognosis for Patients With Peritoneal Metastases From Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

ABSTRACT Background Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in selected patients with colorectal peritoneal metastases. However, outcomes remain heterogeneous, and tumor molecular biology may influence prognosis. Methods We retrospectively reviewed patients with colorectal cancer and peritoneal metastases treated with CRS and HIPEC at Royal Hospital between May 2013 and August 2024. Patients were grouped by presence of genetic mutations (GM) versus no mutations (no‐GM). Primary outcomes were overall survival (OS) and recurrence‐free survival (RFS). Secondary outcomes included morbidity and prognostic factors for recurrence. Results Among 159 patients, 73 (45.9%) had a documented genetic mutation. Genetic mutation was associated with a shorter median RFS (8 months in the GM group vs. 27 months in the no‐GM group; p < 0.001), with 5‐year RFS of 6.0% and 45.3%, respectively. Genetic mutation was also associated with a shorter median OS on univariable analysis (37 months vs. not reached; p = 0.001). On multivariable analysis, genetic mutation status (HR 3.821, 95% CI 2.270–6.432; p < 0.001), PCI > 15 (HR 1.073; p = 0.005), and pre‐HIPEC chemotherapy (HR 2.194; p = 0.003) were independently associated with recurrence. For OS, PCI (HR 1.066; p = 0.037) and poorly differentiated tumor grade (HR 2.946; p = 0.045) were independently associated with survival, whereas genetic mutation status was not (HR 1.477; p = 0.197). Conclusion Genetic mutation was associated with shorter RFS after CRS and HIPEC, and this association persisted after multivariable adjustment. The association with OS was not independent of PCI and tumor grade, suggesting that disease burden may be the main driver of survival. Molecular status may complement established clinicopathological factors in patient assessment; larger prospective studies stratified by mutation type are needed.

Authors

Institutions

Publication Details

Journal
Journal of Surgical Oncology
Published
2026-11-14
DOI
https://doi.org/10.1002/jso.70454
Primary Topic
Intraperitoneal and Appendiceal Malignancies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Impact of Tumor Molecular Profile on Prognosis for Patients With Peritoneal Metastases From Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Manar Mohammed Ahmed Nassr, Khalid Al-Waleed Al Hinai, Sara Al Jahwari
Journal of Surgical Oncology
Intraperitoneal and Appendiceal Malignancies
article

The Impact of Tumor Molecular Profile on Prognosis for Patients With Peritoneal Metastases From Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Manar Mohammed Ahmed Nassr, Khalid Al-Waleed Al Hinai, Sara Al Jahwari
article en

Abstract

ABSTRACT Background Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in selected patients with colorectal peritoneal metastases. However, outcomes remain heterogeneous, and tumor molecular biology may influence prognosis. Methods We retrospectively reviewed patients with colorectal cancer and peritoneal metastases treated with CRS and HIPEC at Royal Hospital between May 2013 and August 2024. Patients were grouped by presence of genetic mutations (GM) versus no mutations (no‐GM). Primary outcomes were overall survival (OS) and recurrence‐free survival (RFS). Secondary outcomes included morbidity and prognostic factors for recurrence. Results Among 159 patients, 73 (45.9%) had a documented genetic mutation. Genetic mutation was associated with a shorter median RFS (8 months in the GM group vs. 27 months in the no‐GM group; p < 0.001), with 5‐year RFS of 6.0% and 45.3%, respectively. Genetic mutation was also associated with a shorter median OS on univariable analysis (37 months vs. not reached; p = 0.001). On multivariable analysis, genetic mutation status (HR 3.821, 95% CI 2.270–6.432; p < 0.001), PCI > 15 (HR 1.073; p = 0.005), and pre‐HIPEC chemotherapy (HR 2.194; p = 0.003) were independently associated with recurrence. For OS, PCI (HR 1.066; p = 0.037) and poorly differentiated tumor grade (HR 2.946; p = 0.045) were independently associated with survival, whereas genetic mutation status was not (HR 1.477; p = 0.197). Conclusion Genetic mutation was associated with shorter RFS after CRS and HIPEC, and this association persisted after multivariable adjustment. The association with OS was not independent of PCI and tumor grade, suggesting that disease burden may be the main driver of survival. Molecular status may complement established clinicopathological factors in patient assessment; larger prospective studies stratified by mutation type are needed.

Journal of Surgical Oncology
Royal Hospital (OM)
Intraperitoneal and Appendiceal Malignancies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon